Search
Gantacurium
go.drugbank.com/drugs/DB05710InvestigationalIt is being developed by Avera Pharmaceuticals.
NCX 1015
go.drugbank.com/drugs/DB05825ExperimentalNCX 1015 is nitric oxide-releasing derivative of prednisolone developed for the treatment of inflammatory bowel disease (IBD) by NicOx SA.
Seliforant
go.drugbank.com/drugs/DB15220InvestigationalSeliforant is under investigation in clinical trial NCT01260753 (Proof of Activity Study of UR-63325 in Allergic Rhinitis Induced by Nasal Challenge).
OMS906
go.drugbank.com/drugs/DB17722InvestigationalOMS906 is a humanized Igg4 monoclonal antibody against mannan-binding lectin-associated serine protease-3 (MASP-3) currently being developed by Omeros.
GC-376 free acid
go.drugbank.com/drugs/DB15796ExperimentalA prodrug of [GC-373], GC-376 has recently been used to test inhibition of SARS-Cov-2 M<sup>pro</sup> _in vitro_, and results show potent inhibition of this target[A219036]. … The compound is known as a direct acting antiviral (DAA) for coronaviruses, and was initially developed using structure-guided design to combat MERS-Cov infections[A219036,A219056].
S-40503
go.drugbank.com/drugs/DB13938ExperimentalS-40503 is an investigational selective androgen receptor modulator (SARM) developed for the treatment of osteoporosis by the Japanese company Kaken Pharmaceuticals.
AAV-dXIAP
go.drugbank.com/drugs/DB17880ExperimentalAAV-dXIAP is a recombinant adeno-associated virus-encoded gene for X-linked mammalian inhibitor of apoptosis protein (XIAP) developed by Neurologix.
Alintegimod
go.drugbank.com/drugs/DB18879InvestigationalAlintegimod is under investigation in clinical trial NCT06362369 (A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy).
Oditrasertib
go.drugbank.com/drugs/DB21526InvestigationalOditrasertib is under investigation in clinical trial NCT05630547 (A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis
LP-2307
go.drugbank.com/drugs/DB17470ExperimentalLP-2307 is an investigational allogeneic large multivalent immunogen (LMI) vaccine developed by Avanir. It was investigated for melanoma.